Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients
详细信息 查看全文
- 作者：R. E. A. Tjon Pian Gi (1)
T. Ilmarinen (2)
E. R. van den Heuvel (3)
L. M. Aaltonen (2)
J. Andersen (4)
J. W. Brunings (5)
M. Chirila (6)
A. Dietz (7)
F. Ferran Vilà (8)
G. Friedrich (9)
H. H. W. de Gier (10)
W. Golusinski (11)
M. Graupp (9)
A. Hantzakos (12)
R. Horcasitas (13)
J. Jackowska (14)
J. C. Koelmel (15)
G. Lawson (16)
F. Lindner (7)
M. Remacle (16)
C. Sittel (15)
V. Weichbold (17)
M. Wierzbicka (14)
F. G. Dikkers (1) - 关键词：Recurrent respiratory papillomatosis ; RRP ; Laryngeal papilloma ; Cidofovir ; Side effects ; Nephrotoxicity ; Neutropenia ; Malignancy
- 刊名：European Archives of Oto-Rhino-Laryngology
- 出版年：2013
- 出版时间：May 2013
- 年：2013
- 卷：270
- 期：5
- 页码：1679-1687
- 全文大小：281KB
- 参考文献：1. Derkay CS (1995) Task-force on recurrent respiratory papillomas—a preliminary report. Arch Otolaryngol Head Neck Surg 121:1386-391 ss="external" href="http://dx.doi.org/10.1001/archotol.1995.01890120044008">CrossRef
2. Armstrong LR, Derkay CS, Reeves WC (1999) Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP task force. Arch Otolaryngol Head Neck Surg 125:743-48
3. Omland T, Akre H, Vardal M, Brondbo K (2012) Epidemiological aspects of recurrent respiratory papillomatosis: a population-based study. Laryngoscope 122:1595-599 ss="external" href="http://dx.doi.org/10.1002/lary.23327">CrossRef
4. Armstrong LR, Preston EJ, Reichert M, Phillips DL, Nisenbaum R, Todd NW, Jacobs IN, Inglis AF, Manning SC, Reeves WC (2000) Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 31:107-09 ss="external" href="http://dx.doi.org/10.1086/313914">CrossRef
5. Lindeberg H, Elbrond O (1990) Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-984. Clin Otolaryngol Allied Sci 15:125-31 ss="external" href="http://dx.doi.org/10.1111/j.1365-2273.1990.tb00444.x">CrossRef
6. Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK (1998) Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J 17:372-76 ss="external" href="http://dx.doi.org/10.1097/00006454-199805000-00005">CrossRef
7. Kashima HK, Shah F, Lyles A, Glackin R, Muhammad N, Turner L, Van Zandt S, Whitt S, Shah K (1992) A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 102:9-3
8. Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L (2004) Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 114:1-3 ss="external" href="http://dx.doi.org/10.1097/01.mlg.000148224.83491.0f">CrossRef
9. Penaloza-Plascencia M, Montoya-Fuentes H, Flores-Martinez SE, Fierro-Velasco FJ, Penaloza-Gonzalez JM, Sanchez-Corona J (2000) Molecular identification of 7 human papillomavirus types in recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 126:1119-123
10. Smith EM, Pignatari SS, Gray SD, Haugen TH, Turek LP (1993) Human papillomavirus infection in papillomas and non-diseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction. Arch Otolaryngol Head Neck Surg 119:554-57 ss="external" href="http://dx.doi.org/10.1001/archotol.1993.01880170080017">CrossRef
11. Rihkanen H, Aaltonen LM, Syrjanen SM (1993) Human papillomavirus in laryngeal papillomas and in adjacent normal epithelium. Clin Otolaryngol Allied Sci 18:470-74 ss="external" href="http://dx.doi.org/10.1111/j.1365-2273.1993.tb00616.x">CrossRef
12. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9-2 ss="external" href="http://dx.doi.org/10.1038/nrc2982">CrossRef
13. Brandwein-Gensler MS, Mahadevia P, Gnepp DR (2009) Non-squamous pathologic diseases of the hypopharynx, larynx, and trachea. In: Gnepp DR (ed) Diagnostic surgical pathology of the head and neck. Saunders Elsevier, Philadelphia
14. Sajan JA, Kerschner JE, Merati AL, Osipov V, Szabo S, Blumin JH (2010) Prevalence of dysplasia in juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 136:7-1 ss="external" href="http://dx.doi.org/10.1001/archoto.2009.179">CrossRef
15. Gerein V, Rastorguev E, Gerein J, Draf W, Schirren J (2005) Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20?years experience. Otolaryngol Head Neck Surg 132:392-94 ss="external" href="http://dx.doi.org/10.1016/j.otohns.2004.09.035">CrossRef
16. Preuss SF, Klussmann JP, Jungehulsing M, Eckel HE, Guntinas-Lichius O, Damm M (2007) Long-term results of surgical treatment for recurrent respiratory papillomatosis. Acta Otolaryngol 127:1196-201 ss="external" href="http://dx.doi.org/10.1080/00016480701200350">CrossRef
17. Silver RD, Rimell FL, Adams GL, Derkay CS, Hester R (2003) Diagnosis and management of pulmonary metastasis from recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg 129:622-29 ss="external" href="http://dx.doi.org/10.1016/j.otohns.2003.08.018">CrossRef
18. Snoeck R, Andrei G, De Clercq E (1998) Specific therapies for human papilloma virus infections. Curr Opin Infect Dis 11:733-37 ss="external" href="http://dx.doi.org/10.1097/00001432-199812000-00014">CrossRef
19. Cundy KC (1999) Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 36:127-43 ss="external" href="http://dx.doi.org/10.2165/00003088-199936020-00004">CrossRef
20. Naiman AN, Roger G, Gagnieu MC, Bordenave J, Mathaut S, Ayari S, Nicollas R, Bour JB, Garabedian N, Froehlich P (2004) Cidofovir plasma assays after local injection in respiratory papillomatosis. Laryngoscope 114:1151-156 ss="external" href="http://dx.doi.org/10.1097/00005537-200407000-00004">CrossRef
21. Shehab N, Sweet BV, Hogikyan ND (2005) Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy 25:977-89 ss="external" href="http://dx.doi.org/10.1592/phco.2005.25.7.977">CrossRef
22. Broekema FI, Dikkers FG (2008) Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 265:871-79 ss="external" href="http://dx.doi.org/10.1007/s00405-008-0658-0">CrossRef
23. Donne AJ, Hampson L, He XT, Day PJ, Salway F, Rothera MP, Homer JJ, Hampson IN (2009) Potential risk factors associated with the use of cidofovir to treat benign human papillomavirus-related disease. Antivir Ther 14:939-52 ss="external" href="http://dx.doi.org/10.3851/IMP1421">CrossRef
24. Bielamowicz S, Villagomez V, Stager SV, Wilson WR (2002) Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope 112:696-99 ss="external" href="http://dx.doi.org/10.1097/00005537-200204000-00019">CrossRef
25. Naiman AN, Ceruse P, Coulombeau B, Froehlich P (2003) Intralesional cidofovir and surgical excision for laryngeal papillomatosis. Laryngoscope 113:2174-181 ss="external" href="http://dx.doi.org/10.1097/00005537-200312000-00024">CrossRef
26. Pransky SM, Albright JT, Magit AE (2003) Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope 113:1583-587 ss="external" href="http://dx.doi.org/10.1097/00005537-200309000-00032">CrossRef
27. Dikkers FG (2006) Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir—a prospective study. Eur Arch Otorhinolaryngol 263:440-43 ss="external" href="http://dx.doi.org/10.1007/s00405-005-1013-3">CrossRef
28. Tanna N, Sidell D, Joshi AS, Bielamowicz SA (2008) Adult intralesional cidofovir therapy for laryngeal papilloma: a 10-year perspective. Arch Otolaryngol Head Neck Surg 134:497-00 ss="external" href="http://dx.doi.org/10.1001/archotol.134.5.497">CrossRef
29. Wierzbicka M, Jackowska J, Bartochowska A, Jozefiak A, Szyfter W, Kedzia W (2011) Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol 268(9):1305-311 ss="external" href="http://dx.doi.org/10.1007/s00405-011-1599-6">CrossRef
30. Gillen D (2011) Direct healthcare professional communication regarding serious adverse reactions following off-label use of Vistide. ss="a-plus-plus" href="http://www.cbg-meb.nl/NR/rdonlyres/FFB51936-EC22-4180-A213-9E907F06A774/0/VistideDHPCletterJanuary2011.pdf">http://www.cbg-meb.nl/NR/rdonlyres/FFB51936-EC22-4180-A213-9E907F06A774/0/VistideDHPCletterJanuary2011.pdf. Accessed 1/12 2011
31. Tjon Pian Gi RE, Dietz A, Djukic V, Eckel HE, Friedrich G, Golusinski W, Hantzakos A, Lawson G, Remacle M, Rihkanen H, Dikkers FG (2012) Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide<sup class="a-plus-plus">?sup>). Eur Arch Otorhinolaryngol 269:361-62 ss="external" href="http://dx.doi.org/10.1007/s00405-011-1804-7">CrossRef
32. McAuley D (04-17-2012). ss="a-plus-plus" href="http://www.globalrph.com/conv_si.htm">http://www.globalrph.com/conv_si.htm. HONcode standard for trustworthy health
33. Silverberg MJ, Thorsen P, Lindeberg H, Ahdieh-Grant L, Shah KV (2004) Clinical course of recurrent respiratory papillomatosis in Danish children. Arch Otolaryngol Head Neck Surg 130:711-16 ss="external" href="http://dx.doi.org/10.1001/archotol.130.6.711">CrossRef
34. McMurray JS, Connor N, Ford CN (2008) Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol 117:477-83
35. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM, FUTURE I and II Study Group (2012) Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 344:e1401 ss="external" href="http://dx.doi.org/10.1136/bmj.e1401">CrossRef
36. Pawlita M, Gissmann L (2009) Recurrent respiratory papillomatosis: indication for HPV vaccination? Dtsch Med Wochenschr 134(Suppl 2):S100–S102 ss="external" href="http://dx.doi.org/10.1055/s-0029-1220219">CrossRef
37. Buchinsky FJ, Donfack J, Derkay CS, Choi SS, Conley SF, Myer CM III, McClay JE, Campisi P, Wiatrak BJ, Sobol SE, Schweinfurth JM, Tsuji DH, Hu FZ, Rockette HE, Ehrlich GD, Post JC (2008) Age of child, more than HPV type, is associated with clinical course in recurrent respiratory papillomatosis. PLoS ONE 3:e2263 ss="external" href="http://dx.doi.org/10.1371/journal.pone.0002263">CrossRef - 作者单位：R. E. A. Tjon Pian Gi (1)
T. Ilmarinen (2)
E. R. van den Heuvel (3)
L. M. Aaltonen (2)
J. Andersen (4)
J. W. Brunings (5)
M. Chirila (6)
A. Dietz (7)
F. Ferran Vilà (8)
G. Friedrich (9)
H. H. W. de Gier (10)
W. Golusinski (11)
M. Graupp (9)
A. Hantzakos (12)
R. Horcasitas (13)
J. Jackowska (14)
J. C. Koelmel (15)
G. Lawson (16)
F. Lindner (7)
M. Remacle (16)
C. Sittel (15)
V. Weichbold (17)
M. Wierzbicka (14)
F. G. Dikkers (1)
1. Department of Otorhinolaryngology Head and Neck Surgery, University of Groningen, University Medical Center Groningen, P.O. box 30001, 9700, RB, Groningen, The Netherlands
2. Department of Otorhinolaryngology Head and Neck Surgery, Helsinki University Hospital, Helsinki, Finland
3. Department of Epidemiology University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4. Ear-Nose-Throat Department, Regionshospitalet Viborg, Viborg, Denmark
5. Department of Otorhinolaryngology/Head and Neck Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands
6. ENT Department, “Iuliu Hatieganu- University of Medicine and Pharmacy, Cluj-Napoca Emergency County Hospital, Cluj-Napoca, Romania
7. Department of Otorhinolaryngology, University of Leipzig, Leipzig, Germany
8. Department of Otorhinolaryngology, Hospital Gral de Catalunya Sant Cugat del Vallès, Barcelona, Spain
9. Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria
10. Department of Otorhinolaryngology/Head and Neck Surgery, Erasmus University Rotterdam, Rotterdam, The Netherlands
11. Department of Otorhinolaryngology, Greater Poland Cancer Centre, Poznan, Poland
12. 1st Department of Otorhinolaryngology, Hippocrateion General Hospital, University of Athens, Athens, Greece
13. ENT Department, Hospital Infantil del Estado de Chihuahua, Chihuahua, Mexico
14. Department of Otolaryngology, Poznan University of Medical Sciences, Poznan, Poland
15. Department of Otorhinolaryngology/Head and Neck Surgery, Klinikum-Stuttgart, Katharinenhospital, Stuttgart, Germany
16. Department of Otorhinolaryngology, University Hospital of Louvain de Mont-Godinne, Yvoir, Belgium
17. Department of Hearing Speech and Voice Disorders, Innsbruck Medical University, Innsbruck, Austria - ISSN：1434-4726
文摘
Intralesional use of cidofovir (Vistide?) has been one of the mainstays of adjuvant therapy in patients with recurrent respiratory papillomatosis (RRP) since 1998. In 2011, a communication provided by the producer of cidofovir addressed very serious side effects concerning its off-label use. As this was a general warning, it was inconclusive whether this would account for its use in RRP. The aim of this study is to determine whether nephrotoxic, neutropenic, or oncogenic side effects have occurred after intralesional use of cidofovir in patients with RRP. Update of recent developments in RRP, a multicentre questionnaire and a multicentre retrospective chart review. Sixteen hospitals from eleven countries worldwide submitted records of 635 RRP patients, of whom 275 were treated with cidofovir. RRP patients received a median of three intralesional injections (interquartile range 2-). There were no statistical differences in occurrence of neutropenia or renal dysfunction before and after cidofovir. There was no statistical difference in occurrence of upper airway and tracheal malignancies between the cidofovir and the non-cidofovir group. In this retrospective patient chart review, no clinical evidence was found for more long-term nephrotoxicity, neutropenia or laryngeal malignancies after the administration of intralesional cidofovir in RRP patients.